Log In
Print
BCIQ
Print
Print this Print this
 

Anti-NKG2D (NN8555) (formerly IPH 2301)

Also known as: NNC 0142-0000-0002

  Manage Alerts
Collapse Summary General Information
Company Innate Pharma S.A.
DescriptionRecombinant human mAb targeting natural killer (NK) and T cells
Molecular Target Natural killer T cells
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationCrohn's disease
Indication DetailsTreat Crohn's disease (CD)
Regulatory Designation

Partner

Novo Nordisk A/S


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today